Lobenzarit (CCA)

  • Y. Shiokawa
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 85)

Abstract

Lobenzarit (CCA) is an antiarthritic agent synthesized by Chugai Pharmaceutical Co., Ltd, Tokyo, Japan. It was selected for investigation as a result of immunopharmacologic screening tests of various immunologic responses induced by the interactions of immunocompetent cells. Extensive studies of lobenzarit have revealed significant effects on the immune system. In animals the compound has proven to be effective in preventing and reducing the severity of glomerulonephritis in NZB/NZW F1 hybrid mice, which are immunologically predisposed to the disease. It also inhibits the development of spontaneous arthritis and nephritis in MRL/Mp-1pr/lpr (MRL/l) mice.

Keywords

Placebo Arthritis Interferon Stratification Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abe C, Shiokawa Y, Ohishi T, Hata S, Takagaki Y (1981) The effect of N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt (CCA) on spontaneous autoimmune disorders in MRL/1 mice. Ryumachi [Suppl] 21: 165Google Scholar
  2. Aritomi H (1985) Radiographic evaluation of the effect of remission inducing drugs in rheumatoid arthritis. In: Nobunaga T (ed) 3rd symposium on clinical trial of drugs–assessments of efficacy for immunomodulators. Nagai-shoten, Osaka, p 103–104Google Scholar
  3. Hata S, Nakano T, Niki R, Takagaki Y, Sakai S (1980) Effect of CCA on the experimental amyloidosis induced by lipopolysaccharide in C3H/He mice. Jpn J Inflammation 1: 145Google Scholar
  4. Itoh K (1983) Mechanism of suppression of chronic inflammation by CCA. I. Effect of CCA on activated macrophage. 4th Conference of the Japanese Society of Inflammation, TokyoGoogle Scholar
  5. Itoh K, Kurane I, Saito F, Kawakami K, Kosaka S, Kumagai K (1983) The IFN-inducing ability and immunoregulatory action of CCA. Clin Immunol 15: 242Google Scholar
  6. Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and re- lated conditions by standard reference films. Acta Radiol [Diagn] (Stockh) 18: 481Google Scholar
  7. Maeda A (1985) A long-term clinical trial of CCA. In: Nobunaga T (ed) 3rd symposium on clinical trials of drugs — assessments of efficacy for immunomodulators. Nagaishoten, Osaka, p 78–79Google Scholar
  8. Nakano T, Yamashita Y, Ohsugi Y, Sugawara Y, Hata S, Takagaki Y (1983) The effect of CCA (lobenzarit disodium) on the suppressor T cell function and the production of autoantibodies in NZB x NZW F1 mice. Immunopharmacology 5: 293PubMedCrossRefGoogle Scholar
  9. Nakazawa T, Abe C, Shiokawa Y, Kamijo K (1984) Carboxyphenyl chloroanthranilic acid ( CCA) in the modulation of immune response in mice. Int J Tissue React 6: 23Google Scholar
  10. Ogawa H, Tsunematsu T (1982) Effects of immunomodulating agents on human suppressor T lymphocytes. Allergy 31: 207PubMedGoogle Scholar
  11. Ohsugi Y, Nakano T, Hata S, Matsuno T, Nishii Y, Takagaki Y (1977 a) Disodium N-(2carboxyphenyl)-4-chloroanthranilate: enhancement of immune response in mice. Chem Pharm Bull (Tokyo) 25: 2143Google Scholar
  12. Ohsugi Y, Hata S, Tanemura M, Nakano T, Matsuno T, Takagaki Y, Nishii Y, Shindo M (1977 b) N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt: a novel anti-arthritic agents without anti-inflammatory and immunosuppressive activities. J Pharm Pharmacol 29: 636Google Scholar
  13. Ohsugi Y, Nakano T, Hata S, Niki R, Matsuno T, Nishii Y, Takagaki Y (1978) N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt: prevention of autoimmune kidney disease in NZB/NZW F1 hybrid mice. J Pharm Pharmacol 30: 126PubMedCrossRefGoogle Scholar
  14. Ohsugi Y, Nakano T, Hata S (1983) A novel anti-arthritic agent, CCA (lobenzarit sodium); and the role of thymus-derived lymphocytes in the inhibition of rat adjuvant arthritis. Immunopharmacology 6: 15Google Scholar
  15. Ohsugi Y, Nakano T, Ueno K, Fukui H, Niki R, Sugawara Y, Hata S ( 1985 a) An immunopharmacological profile of lobenzarit disodium ( CCA), a new immunomodulating anti-rheumatic drug. Int J Immunother 1: 85Google Scholar
  16. Ohsugi Y, Nakano T, Ueno K, Sugawara Y ( 1985 b) CCA pharmacology: preclinical evaluation for effects on experimental arthritis and immunomodulative effects. In: Nobunaga T (ed) 3rd symposium on clinical trials of drugs — assessments of efficacy for immunomodulators. Nagai-shoten, Osaka, p 67–69Google Scholar
  17. Shiokawa Y, Abe C (1985) Immunotherapy of connective tissue disease. Proceedings of the 3rd international conference on immunopharmacology, Florence, Italy, 6–9 May 1985. In: Chedid L (ed) Advances in immunopharmacology, p 75–81Google Scholar
  18. Shiokawa Y, Horiuchi Y, Mizushima Y, Kageyama T, Shichikawa K, Ofuji T, Honma M et al. (1984) A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, on rheumatoid arthritis. J Rheumatol 11: 615PubMedGoogle Scholar
  19. Sonozaki T, Mitsui H (1984) T cell abnormality in rheumatoid arthritis and effect of immunopotentiator. Ryumachi 24: 3PubMedGoogle Scholar
  20. Tanemura M, Kaiho S, Mizuno K, Nogaki K, Hata S, Takagaki Y (1984) Effect of an immunomodulator agent CCA on inflammatory response in various animal models. Jpn J Inflammation 4: 239Google Scholar
  21. Watanabe H, Yanagawa A, Shoji Y, Mizushima Y (1983) A study of the immunomodulating effect of CCA. Jpn J Inflammation 3: 156Google Scholar
  22. Yamamoto I, Ohmori Y, Sasano M (1982) CCA: an immunopharmacological profile in vivo and in vitro. Drug Exp Clin Res 8: 5Google Scholar
  23. Yamamoto I, Ohmori H, Sasano M (1983) Effect of N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt ( CCA) on the induction of helper and suppressor T cells in vitro and in vivo. Jpn J Pharmacol 33: 859Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Y. Shiokawa

There are no affiliations available

Personalised recommendations